Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600115942) titled 'A single-center, non-randomized controlled study of the efficacy and safety of QL1706 combined with chemotherapy versus chemotherapy alone in the first-line treatment of recurrent/metastatic endometrial cancer' on Jan. 4.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Nantong Cancer Hospital
Condition:
Endometrial cancer
Intervention:
Group A( QL1706 + carboplatin + paclitaxel):Paclitaxel 135~175 mg/m^2, intravenous infusion, at least 3 hours
Carboplatin AUC 4~5, intravenous infusion, at least 1 hour
QL1706 5 mg/kg, 30~60 minute intravenous infusion, combined with ch...